Scarica il documento in formato pdf (1196 KB) - ANCE

narico per malattia di un vaso e angina lieve 19.000; trapianto
di rene 5000; trapianto di cuore 8000; dialisi domiciliare
18.000; dialisi ospedaliera 22.000; eritropoietina in
pazienti dializzati con anemia, ipotizzando una riduzione
di mortalità del 10%, 55.000; eritropoietina in pazienti
dializzati con anemia, ipotizzando assenza di effetti sulla
sopravvivenza, 127.000.
BIBLIOGRAFIA
1. Bristow MR, Saxon LA, Boehmer J et al. Comparison of
medical therapy, pacing and defibrillation in heart failure
(COMPANION). Cardiac resynchronisation therapy with
or without an implantable defibrillator in advanced chronic
heart failure. N Engl J Med 2004; 350: 2140-50.
2. Cleland J, Daubert JC, Erdmann E et al. The effect of cardiac
resynchronization on morbidity and mortality in heart failure
(CARE-HF). N Engl J Med 2005; 352: 1539-49.
3. National Institute for Health and Clinical Excellence
(NICE). NICE technology appraisal guidance 120. Cardiac
resynchronisation therapy for the treatment of heart failure.
May 2007. Http://guidance.nice.org.uk.
4. Josephson M, Wellens HJ. Implantable defibrillators and
sudden cardiac death. Circulation 2004; 109: 2685-91.
5. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of
a defibrillator in patients with myocardial infarction and
reduced ejection fraction. New Engl J Med 202; 346: 877-83.
6. Bardy GH, Lee KL, Mark DH et al. Amiodarone or
implantable cardioverter-defibrillator for congestive heart
failure. New Engl J Med; 2005; 342: 225-37.
7. Ezekowitz JA, Rowe BH, Dryden DM et al. Systematic
review: implantable cardioverter defibrillators for adults
with left ventricular systolic dysfunction. Arch Intern Med
2007; 147: 251-62.
8. Medina-Ravell VA, Lankipalli RS, Yan GX et al. Effect of epicardial
biventricular pacing to prolong QT interval and
increase transmural dispersion of repolarization. Does
resynchronization therapy pose a risk for patients predisposed
to long QT or torsade de pointes? Circulation
2003; 107:740-6.
9. Spragg DD e Kass DA. Pathobiology of left ventricular dyssynchrony
and resynchronization. Prog Cardiovasc Dis
2006; 49: 26-41.
10. Cleland JG, Daubert JC, Erdmann E et al. Longer term
effects of cardiac resynchronization therapy on mortality
in heart failure. CARE-HF trial extension phase. Eur Heart J
2006; 27: 1928-32.
11. Ermis C, Seutter R, Zhu AX et al. Impact of upgrade to cardiac
resynchronization therapy on ventricular arrhythmia
frequency in patients with implantable cardioverter-defibrillator.
JACC 2005; 46: 2258-63.
12. Lin G, Rea RF, Hammil SC et al. Effect of cardiac resynchronization
therapy on occurrence of ventricular arrhythmias
in patients with implantable cardioverter defibrillators
undergoing upgrade to cardiac resynchronization therapy
devices. Heart 2008; 94: 186-190.
13. Mc Alister FA, Ezekowitz J, Hooton N et al. Cardiac resynchronization
therapy for patients with left ventricular systolic
dysfunction. A systematic review. JAMA 2007; 297:
2502-14.
14. Lam SKH, Owen A. Combined resynchronisation and
implantable defibrillator therapy in left ventricular dysfunction.
Bayesan network meta-analysis of randomized
controlled trials. Br Med J 2007; 335: 925-35.
37
E. Enia La risincronizzazione cardiaca. V° Defibrillatore e CRT. Analisi cost-effectiveness
15. Friedewald VE, Boehmer JP, Kowal RC et al. The editor’s
roundtable. Cardiac resynchronization therapy. Am J
Cardiol 2007; 1145-52.
16. Saxon LA. More is better with cardiac resynchronization
therapy, but is it enough? Eur Heart J 2006; 27: 1891-2.
17. ACC/AHA/ESC Guidelines for management of patients
with ventricular arrhythmias and the prevention of sudden
cardiac death. Circulation 2006; 114; 385-484.
18. Hohnloser SH, Kuck KH, Donan P et al. Prophylactic use of
an implantable cardioverter-defibrillator after acute myocardial
infarction. New Engl J Med 2004; 351: 2481-8.
19. Buxton AE, Lee KL, Hafley JE et al. Relation of ejection fraction
and inducible ventricular tachycardia in mode of
death in patients with coronary artery disease. An analysis
of patients enrolled in the Multicenter Unsustained
Tachycardia Trial. Circulation 2002; 106: 2466-72.
20. Buxton AE, Lee KL, Di Carlo L et al. Electrophysiologic
testing to identify patients with coronary heart disease
who are at risk for sudden death. New Engl J Med 2000;
342: 1937-45.
21. Cantillon DJ, Stein KM, Markowitz SM et al. Predictive
value of microvolt T-wave alternans in patients with left
ventricular dysfunction. JACC 2007; 50: 166-73.
22. Salerno-Uriarte JA, De Ferrari G M, Klersy K et al.
Prognostic value of T-wave alternans in patients with heart
failure due to nonischemic cardiomyopathy. JACC 2007;
50: 1896-904.
23. Cleland JG, Coletta AP, Abdellah AT et al. Clinical trials
update from the American Heart Association 2006. Eur J
Heart Fail 2007; 9: 92-7.
24. Chow T, Kereiakes DJ, Bartone C et al. Microvolt-T-wavealternans
identifies patients with ischemic cardiomyopathy
who benefit from implantable cardioverter-defibrillator
therapy. JACC 2007; 49: 50-8.
25. Cleland JG, Coletta AP, Abdellah AT et al. Clinical trials
update from the American Heart Association 2007. Eur J
Heart Fail 2008; 10: 102-8.
26. Goldenberg I, Vyas AK, Hall J et al. Risk stratification for
primary implantation of a cardioverter-defibrillator in
patients with ischemic left ventricular dysfunction. JACC
2008; 51: 288-96.
27. MERIT-HF study group. Effect of metoprolol CR/XL in
chronic heart failure. Lancet 1999; 353: 2001-7.
28. Angell M. The doctor as double agent. Kennedy Institute
of Ethics Journal 1993; 3: 279-86.
29. Barnett D, Phillips S, Longson C. Cardiac resynchronisation
therapy for the treatment of heart failure. NICE technology
appraisal guidance. Heart 2007; 93: 1134-5.
30. Nichol G, Kaul P. Huszti E et al. Cost-effectiveness of cardiac
resynchronization therapy in patients with symptomatic
heart failure. Ann Inter Med 2004; 141: 343-51.
31. Calvert MJ, Freemantle N, Yao G et al. Cost-effectiveness
of cardiac resynchronization therapy. Results from the
CARE-HF trial. Eur Heart J 2005; 26: 2681-8.
32. Yao G, Freemantle N, Calvert MJ et al. The long-term costeffectiveness
of cardiac resynchronization therapy with or
without an implantable cardioverter-defibrillator. Eur
Heart J 2007; 28: 42-51.
33. Caro JJ, Guo S, Ward A et al. Modelling the economic and
health consequences of cardiac resynchronization therapy
in the UK. Curr Med Res Opin 2006; 22: 1171-9.
34. Hlatky MA. Cost-effectiveness of cardiac resynchronization
therapy. JACC 2005; 46: 2322-4.
35. Taylor C. Il disagio della modernità. Laterza, Roma-Bari,
1994 p. 8.
36. Mason J, Drummond M, Torrance G. Some guidelines on the
use of cost-effectiveness league tables. BMJ 1993; 306: 570-2.